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Main Text: 
Disorders of the brain are becoming more prevalent over time and are threatening not only 
the quality of life of millions of citizens but are also creating major challenges for the 
national health systems. Restless Legs Syndrome (RLS) (or Willis/Ekbom Disease) is one of 
the most common neurological disorders inducing significant personal, social and economic 
burden. With an adult prevalence of around 2.7% in the general population, RLS is 
underdiagnosed [1], estimated to be affecting 20 million of European citizens. Recent data 
from the “Value of treatment for brain disorders” research project, conducted by the 
European Brain Council*, showed that RLS is the fifth more expensive neurological disorder 
after mood disorders and dementia. 
Notably, RLS prevalence in hemodialysis (HD) patients is much higher than in the general 
population reaching approximately 30% [2, 3]. Uremic RLS has been frequently associated 
with increased morbidity and enhanced mortality in HD patients, linked to cardiovascular 
diseases [4]. A recent 3-year mortality study showed for the first time that the diagnosis of 
RLS according to the essential criteria of the International RLS Study Group does not seem to 
influence mortality in HD patients [5]. Mortality rate was 15.6% (5.2%/yr) in RLS-HD patients 
and 22.3% (7.4%/yr) in non-RLS HD patients with no significant association between RLS and 
3-year mortality, either with age and gender as covariates. In this current issue, an 
unprecedented 15-year follow-up RLS survival study is presented by Baiardi et al [REF] 
showing that RLS-HD patients presented a lower mortality rate compared to those HD 
patients without the syndrome [63.8% (4.3%/yr) RLS-HD vs 87.6% (5.8%/yr) non-RLS HD, p = 
0.04]. Similarly, the mortality rate was not influenced by gender (p = 0.15) and even more 
importantly, by RLS severity (p = 0.11). In addition, the study by Baiardi et al, [REF] showed 
no difference among the causes of death between the two groups in contrast to studies 
linking RLS to cardiovascular diseases [4]. The studies by Stefanidis et al [5] and by Baiardi et 
al, [REF] clearly suggest that mortality in HD patients is not influenced by the presence of 
RLS/WED, with no clinical evidence linking uremic RLS/WED and cardiovascular mortality. 
Considering the discordant literature results on the mortality risk in uremic RLS patients, 
and the fact that cardiovascular disease is the number one cause of death in HD patients, 
the recent evidence by Baiardi et al, [REF] will help design the next prospective studies to 
address other possibly non-traditional uremia-related variables for reducing cardiovascular 
mortality and to improve patients’ survival and quality of life. RLS symptoms during HD 
sessions and during rest hours continue to be one of the most disturbing disease factors for 
HD patients. RLS impacts on affecting patients’ quality of life and their overall health mainly 
by increasing depressive symptoms. Unfortunately, due to limited knowledge of the disease 
and possible treatment, patients often go through long periods of suffering until the correct 
diagnosis is made and proper treatment started. This leads to an unnecessary burden on 
health care budgets and severely deterioration of patients’ mood status. Extensive 
education of both patients and nephrologists is needed to improve this situation. Since at 
the moment there is no cure and the existing available treatments are far from optimal, 
more research into the pathophysiology of uremic RLS and its disease mechanism is needed 
to provide specific symptomatic and future curative treatments.  
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